Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS-GCGRRx - Dose Level 1 · 1 trial · 1 indication
Change from Baseline to Week 14
| Arm | Type | Description |
|---|---|---|
| ISIS-GCGRRx Dose Level 1 | EXPERIMENTAL | ISIS-GCGRRx Dose Level 1 |
| ISIS-GCGRRx Dose Level 2 | EXPERIMENTAL | ISIS-GCGRRx Dose Level 2 |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| ISIS-GCGRRx - Dose Level 1 | DRUG | 3 doses on alternate days during the first week and then once weekly for 12 weeks |
| ISIS-GCGRRx - Dose Level 2 | DRUG | 3 doses on alternate days during the first week and then once weekly for 12 weeks |
| Placebo | DRUG | 3 doses on alternate days during the first week and then once weekly for 12 weeks |
Inclusion Criteria: * Male or female, age 18 to 75 * BMI greater than or equal to 25 * HbA1c greater than or equal to 7.5% and less than or equal to 10.5% * Type 2 Diabetes Mellitus and on stable dose of oral metformin * Agree to conduct home-based (fasted) blood glucose testing as directed Exclus...